Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of DMT in Humans
NCT06671977Phase 1Recruiting
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DMT in major depressive disorder (MDD) (5 arms). Primary endpoints: Safety of Physiological indices, Psychedelic Effects and 7 more. Started Mar 2025; status: recruiting.
02
Drugs
DMT
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06671977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671977.